Evoke Pharma Inc (NASDAQ:EVOK) Expected to Announce Earnings of -$0.06 Per Share

Equities analysts forecast that Evoke Pharma Inc (NASDAQ:EVOK) will post earnings per share of ($0.06) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Evoke Pharma’s earnings. Evoke Pharma posted earnings of ($0.10) per share in the same quarter last year, which would suggest a positive year over year growth rate of 40%. The business is expected to issue its next earnings results on Wednesday, March 4th.

According to Zacks, analysts expect that Evoke Pharma will report full-year earnings of ($0.31) per share for the current financial year. For the next fiscal year, analysts forecast that the firm will post earnings of ($0.19) per share. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Evoke Pharma.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.02.

A number of brokerages have commented on EVOK. HC Wainwright reiterated a “hold” rating on shares of Evoke Pharma in a research report on Monday. Zacks Investment Research raised Evoke Pharma from a “hold” rating to a “buy” rating and set a $1.75 target price for the company in a research note on Wednesday.

EVOK stock traded down $0.02 during trading on Friday, hitting $1.57. The company had a trading volume of 6,312 shares, compared to its average volume of 557,609. The firm has a 50-day moving average price of $1.11 and a 200-day moving average price of $0.90. Evoke Pharma has a 12 month low of $0.50 and a 12 month high of $3.26. The stock has a market cap of $38.46 million, a price-to-earnings ratio of -3.41 and a beta of 1.86.

An institutional investor recently bought a new position in Evoke Pharma stock. Marshall Wace LLP acquired a new stake in Evoke Pharma Inc (NASDAQ:EVOK) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 92,406 shares of the specialty pharmaceutical company’s stock, valued at approximately $139,000. Marshall Wace LLP owned approximately 0.40% of Evoke Pharma at the end of the most recent reporting period. 6.57% of the stock is owned by institutional investors.

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Further Reading: How to invest in a bear market

Get a free copy of the Zacks research report on Evoke Pharma (EVOK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Evoke Pharma (NASDAQ:EVOK)

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit